Previous 10 | Next 10 |
Substantial progress achieved across three anti-Tau clinical development programs; all clinical and preclinical programs remain on track to generate value in the second half of 2020 Top line Phase 2 data expected in the second half of 2020 for anti-Tau antibody semorinemab CHF 262.5 mill...
AC Immune (NASDAQ: ACIU ) has initiated preclinical studies for therapeutic antibody targeting TDP-43 (TAR DNA-binding protein 43), that functions primarily in the nucleus as a regulator of gene transcription and RNA metabolism. More news on: AC Immune SA, Healthcare stocks new...
First-in-class TDP-43 antibody developed using SurpraAntigen™ platform The only TDP-43 antibody with reported in vivo activity LAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical compan...
AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical results presented at AAIC on the Company’s alpha-synuclein positron emission tomography -(PET)...
AC Immune SA (NASDAQ: ACIU ) announces new preclinical data on its next-generation alpha-synuclein positron emission tomography-(PET) tracer. The results were presented virtually at the Alzheimer's Association International Conference. More news on: AC Immune SA, Healthcare stocks...
Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer™ platform for generating highly selective small molecule diagnostics LAUSANNE, Sw...
LAUSANNE, Switzerland, July 23, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced two oral presentations will be delivered at this year’s Alzhei...
Principia Biopharma Perks Up on Sanofi Rumors Principia Biopharma (PRNB) shot up due to swirling rumors regarding Sanofi's (SNY) interest in the firm. The French pharma company is currently looking to expand its presence in the United States and is weighing different options. Principia is ...
Shares of AC Immune (NASDAQ: ACIU) a re up 26% at 2:23 p.m. EDT after the biotech revealed top-line results from an early-stage clinical trial testing its Alzheimer's disease vaccine, ACI-35.030, which A C Immune is developing with Johnson & Johnson (NYSE: JNJ) . Based on the ...
DENVER, Colo., July 16, 2020- Today’s biotech headlines include developments from Emmaus Life Sciences, Inc. (OTCQB:EMMA), AC Immune SA (NASDAQ:ACIU), and Nabriva Therapeutics plc (NASDAQ:NBRV). Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, announced ...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...